2024
Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting
Leapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, Sprenkle P, Ross A. Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting. European Urology Oncology 2024 PMID: 39098389, DOI: 10.1016/j.euo.2024.07.010.Peer-Reviewed Original ResearchDecipher genomic classifierRisk of metastasisBiochemical recurrenceRadical prostatectomyGenomic classifierDecipher testProstate cancerProstate Risk Assessment Postsurgical ScoreRisk of biochemical recurrencePatient's prostate cancerRisk of cancer recurrencePathological risk factorsProstate cancer outcomesCox proportional hazards regressionRetrospective cohort studyElectronic health record dataReal-world settingsProportional hazards regressionHealth record dataReal-world practice settingsProstate biopsyRP specimensOncological outcomesPrognostic significanceMedian ageAssociation between pelvic lymph node dissection and survival among patients with prostate cancer treated with radical prostatectomy
Kim I, Wang A, Corpuz G, Sprenkle P, Leapman M, Brito J, Renzulli J, Kim I. Association between pelvic lymph node dissection and survival among patients with prostate cancer treated with radical prostatectomy. Prostate International 2024, 12: 70-78. PMID: 39036758, PMCID: PMC11255894, DOI: 10.1016/j.prnil.2024.01.002.Peer-Reviewed Original ResearchPelvic lymph node dissectionBenefit of pelvic lymph node dissectionGleason grade groupLymph node dissectionProstate cancer patientsRadical prostatectomyNode dissectionProstate cancer treated with radical prostatectomyCancer patientsAssociated with improved OSTime of radical prostatectomyGrade groupSurvival of prostate cancer patientsMedian PSA valuePre-operative characteristicsProstate cancer-specificTime of RPLog-rank testKaplan-Meier curvesPSA valuesSurvival benefitProstate cancerMedian ageClinical benefitCancer-specificAdaption and National Validation of a Tool for Predicting Mortality from Other Causes Among Men with Nonmetastatic Prostate Cancer
Justice A, Tate J, Howland F, Gaziano J, Kelley M, McMahon B, Haiman C, Wadia R, Madduri R, Danciu I, Leppert J, Leapman M, Thurtle D, Gnanapragasam V. Adaption and National Validation of a Tool for Predicting Mortality from Other Causes Among Men with Nonmetastatic Prostate Cancer. European Urology Oncology 2024, 7: 923-932. PMID: 38171965, DOI: 10.1016/j.euo.2023.11.023.Peer-Reviewed Original ResearchVeterans Health AdministrationCharlson Comorbidity IndexNon-prostate cancer mortalityProstate cancer mortalityNonmetastatic prostate cancerComorbidity indexCancer mortalityProvider estimationProstate cancerHealth AdministrationUS Veterans Health AdministrationElectronic health record-based toolsYear of diagnosisRisk of deathObservational cohortMedian ageNonmetastatic cancerPredicting MortalityC-statisticHispanic ethnicityTreatment groupsMortalityCancerNational validationAge
2023
Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation
Leapman M, Wang R, Loeb S, Seibert T, Gaylis F, Lowentritt B, Brown G, Chen R, Lin D, Witte J, Cooperberg M, Catalona W, Gross C, Ma X. Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation. Journal Of Urology 2023, 209: 710-718. PMID: 36753746, DOI: 10.1097/ju.0000000000003159.Peer-Reviewed Original ResearchConceptsIntermediate-risk prostate cancerMixed-effects Poisson regressionPSA testingProstate biopsyProstate cancerEffects Poisson regressionMedicare beneficiariesPoisson regressionAdditional prostate biopsyRetrospective cohort studyProstate MRILocalized prostate cancerRepeat prostate biopsyRate of biopsyRace/ethnicityCensus tract povertyMedian followCohort studyMedian ageMonitoring testsProvider factorsPSA testClinical riskBiopsySociodemographic factors
2022
Factors associated with the quality of end-of-life care for patients with metastatic renal cell carcinoma.
Dzimitrowicz H, Wilson L, Jackson B, Spees L, Baggett C, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Dinan M, Wheeler S. Factors associated with the quality of end-of-life care for patients with metastatic renal cell carcinoma. Journal Of Clinical Oncology 2022, 40: 300-300. DOI: 10.1200/jco.2022.40.6_suppl.300.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anti-cancer agentsRenal cell carcinomaSEER-MedicareDays of lifeSystemic therapyICU admissionCell carcinomaOdds ratioLife careSEER-Medicare cohortSystemic therapy useMultivariable logistic regressionUse of hospiceQuality of endHigh-quality endMRCC diagnosisAnti-cancer agentsMost patientsOlder patientsHospital admissionMedian ageTherapy useImmunotherapy treatmentRetrospective study
2020
Predicting prostate cancer death among 98,994 veterans: Differences by race/ethnicity.
Janet T, Danciu I, Justice A, Leapman M, McMahon B, Wadia R. Predicting prostate cancer death among 98,994 veterans: Differences by race/ethnicity. Journal Of Clinical Oncology 2020, 38: e17609-e17609. DOI: 10.1200/jco.2020.38.15_suppl.e17609.Peer-Reviewed Original ResearchProstate cancer deathNon-Hispanic blacksNon-Hispanic whitesVeterans Affairs Healthcare SystemRace/ethnicityHazard ratioGleason scoreCancer deathProstate cancerU.S. Veterans Affairs healthcare systemProstate cancer disease progressionDistant metastatic diseaseProstate cancer mortalityCancer disease progressionLocalized diseasePSA levelsMedian ageMetastatic diseaseLymph nodesPrognostic indexCancer mortalityTumor stageDisease progressionCox modelAge strataAssociation of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era.
Miccio J, Ma S, Oladeru O, Yang D, Peters G, Jethwa K, Park H, Hurwitz M, Leapman M, Sprenkle P, Nguyen P, Yu J, Johung K. Association of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era. Journal Of Clinical Oncology 2020, 38: 748-748. DOI: 10.1200/jco.2020.38.6_suppl.748.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaCytoreductive nephrectomyICI eraImproved overall survivalNational Cancer DatabaseOverall survivalIFN eraFuhrman gradeBenefit of CNEfficacy of ICIsClinical T stageCox regression analysisTreatment facility typeRenal cell carcinomaCARMENA trialInterferon eraMultivariable associateN0 diseaseOS benefitProspective reevaluationMedian ageT stageCell carcinomaCancer DatabasePartial nephrectomy
2019
The nonsurgical management of upper tract urothelial carcinoma: A role for active surveillance?
Syed J, Nguyen K, Javier-Desloges J, Leapman M, Raman J, Shuch B. The nonsurgical management of upper tract urothelial carcinoma: A role for active surveillance? Journal Of Clinical Oncology 2019, 37: 485-485. DOI: 10.1200/jco.2019.37.7_suppl.485.Peer-Reviewed Original ResearchUpper tract urothelial cancerMedian overall survivalOverall survivalTumor gradeCox proportional hazards regression modelProportional hazards regression modelsNational Cancer DatabaseKaplan-Meier methodHazards regression modelsHigh-grade tumorsGovernment health insuranceDefinitive surgeryDefinitive therapyOlder patientsPatient demographicsMedian ageWorse survivalUrothelial cancerGrade tumorsAlternative therapiesCancer DatabaseOS differenceRadiation therapyPatientsSurvival analysis
2018
Comparison of a low-cost immunohistochemistry marker panel with a cell-cycle progression assay for the prediction of outcome after radical prostatectomy.
Leapman M, Nguyen H, Cowan J, Xue L, Stohr B, Simko J, Cooperberg M, Carroll P. Comparison of a low-cost immunohistochemistry marker panel with a cell-cycle progression assay for the prediction of outcome after radical prostatectomy. Journal Of Clinical Oncology 2018, 36: 118-118. DOI: 10.1200/jco.2018.36.6_suppl.118.Peer-Reviewed Original ResearchPCa-specific mortalityRadical prostatectomyBiochemical recurrenceCCP scoreIHC panelCell cycle progression scoreExpression statusERG expressionCox proportional hazards regressionRisk of BCRPositive ERG expressionProportional hazards regressionProstate cancer riskPrediction of outcomeHigh Ki67Median ageIndependent predictorsPathologic characteristicsHazards regressionPrognostic utilityIHC statusInstitutional databaseLocalized PCaC-indexImmunohistochemistry panel
2017
Active Surveillance in Younger Men With Prostate Cancer
Leapman MS, Cowan JE, Nguyen HG, Shinohara KK, Perez N, Cooperberg MR, Catalona WJ, Carroll PR. Active Surveillance in Younger Men With Prostate Cancer. Journal Of Clinical Oncology 2017, 35: jco.2016.68.005. PMID: 28346806, PMCID: PMC5466007, DOI: 10.1200/jco.2016.68.0058.Peer-Reviewed Original ResearchConceptsBiopsy-based Gleason scoreActive surveillanceAssociation of ageProstate cancerDefinitive treatmentRadical prostatectomyYounger patientsGleason scoreMultivariable Cox proportional hazards regressionYounger ageLow-risk prostate cancerCox proportional hazards regressionGleason score upgradeInitial active surveillanceRelated end pointsCox regression analysisKaplan-Meier methodYounger patient ageProportional hazards regressionPrimary study objectiveInitial biopsyMedian agePatient ageHazards regressionBiochemical outcomes
2015
Association of magnitude of cancer of the prostate risk assessment score change following biopsy gleason upgrade during prostate cancer active surveillance with adverse pathology at prostatectomy.
Leapman M, Ameli N, Chu C, Welty C, Hussein A, Cooperberg M, Carroll P. Association of magnitude of cancer of the prostate risk assessment score change following biopsy gleason upgrade during prostate cancer active surveillance with adverse pathology at prostatectomy. Journal Of Clinical Oncology 2015, 33: 76-76. DOI: 10.1200/jco.2015.33.7_suppl.76.Peer-Reviewed Original ResearchCAPRA scoreActive surveillanceProstate cancerAdverse pathologyBiopsy GleasonProstate cancer active surveillanceIntermediate-risk prostate cancerProstate Risk Assessment (CAPRA) scoreRisk categoriesMultivariate logistic regression modelAdverse surgical pathologyRisk prostate cancerAdverse pathological outcomesRisk assessment scoreLogistic regression modelsBiopsy upgradeGleason upgradeSurveillance biopsiesMedian ageRepeat biopsyInitial diagnosisSubsequent biopsyRadical prostatectomyMedian changeSurgical pathology